NCT03402438View on ClinicalTrials.gov

Renal Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

December 4, 2018

Study Completion Date

March 19, 2019

Conditions
Clinical Trial, Phase I
Interventions
DRUG

Fulacimstat (BAY1142524)

single oral dose of 25 mg immediate-release tablet BAY1142524

Trial Locations (1)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY